(Q33766128)

29 July 2017

0 references

1 reference

title

Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis (English)

1 reference

29 July 2017

1 reference

Yan Chen

1

1 reference

29 July 2017

Xiao Yan Yang

2

1 reference

29 July 2017

Michael Zeckel

3

1 reference

29 July 2017

Chris Killian

4

1 reference

29 July 2017

Kenneth Hornbuckle

5

1 reference

29 July 2017

Arie Regev

6

1 reference

29 July 2017

Simon Voss

7

1 reference

29 July 2017

publication date

1 January 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

34

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

73-82

1 reference

Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11539560-000000000-00000

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539560-000000000-00000

Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539560-000000000-00000

Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539560-000000000-00000

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11539560-000000000-00000

Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.

21 January 2018

1 reference

12 December 2020

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

1 reference

12 December 2020

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

1 reference

12 December 2020

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

1 reference

12 December 2020

Jaundice associated with severe bacterial infection in young infants

1 reference

12 December 2020

Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Canc

1 reference

12 December 2020

Linezolid for the treatment of infections caused by Gram-positive pathogens in China

1 reference

12 December 2020

Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice

1 reference

12 December 2020

Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial

1 reference

12 December 2020

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

12 December 2020

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

1 reference

12 December 2020

Mechanisms of drug-induced liver injury.

1 reference

12 December 2020

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

12 December 2020

Characterization of drug-specific T cells in lamotrigine hypersensitivity

1 reference

12 December 2020

Vancomycin: a 50-year reassessment

1 reference

12 December 2020

Introduction to vancomycin

1 reference

12 December 2020

Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer

1 reference

12 December 2020

Evidence-Based Medicine (EBM) in practice: applying number needed to treat and number needed to harm

1 reference

12 December 2020

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

1 reference

12 December 2020

Vancomycin-induced elevation of liver enzyme levels

1 reference

12 December 2020

Abnormalities in bilirubin and liver enzyme levels in adult patients with bacteremia. A prospective study

1 reference

12 December 2020

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

1 reference

12 December 2020

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

1 reference

12 December 2020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

12 December 2020

Role of Proinflammatory Cytokines in Acetaminophen Hepatotoxicity

1 reference

12 December 2020

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

1 reference

12 December 2020

A critical review of the dosage of teicoplanin in Europe and the USA.

1 reference

12 December 2020

Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms

1 reference

12 December 2020

Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan

1 reference

12 December 2020

10.2165/11539560-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1017829782

0 references

1 reference